Stock vs Stock Comparison

Thermo Fisher Scientific Inc. vs AbbVie Inc.

ABBV wins the Tale of the Tape 6–3.

TMO$482.08
ABBV$217.13

🏆 Tale of the Tape

36
TMOABBV
15.0%Profitability (Net Margin)6.9%
27.1xValuation (P/E)106.2x
7.2%Efficiency (ROIC)8.3%
4/9Health (Piotroski F)7/9
3.5Safety (Altman Z)2.0
3.9%Growth (Rev YoY)8.6%
0.41Risk (Sharpe 1Y)0.61
1.06xBalance Sheet (D/E)-42.50x
2.99%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.397
252-Day Correlation
0.123
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricTMOABBV
Market Cap$183.0B$384.7B
P/E Ratio27.1x106.2x
Forward P/E18.0x13.4x
P/B3.47x-57.80x
Dividend Yield0.38%3.18%
Beta0.880.30

Quantitative Metrics

MetricTMOABBV
DCF Fair Value$110.23$126.26
DCF Upside-78.6%-38.9%
Piotroski F4/97/9
Altman Z3.512.01
Beneish M-2.45-2.87
FCF Yield2.99%4.23%
Net Debt/EBITDA2.3x3.0x
ROIC7.2%8.3%
WACC9.7%7.4%
ROIC – WACC-2.5pp0.8pp
Gross Margin40.9%70.2%
Net Margin15.0%6.9%
Rev Growth YoY3.9%8.6%
Sharpe (1Y)0.410.61
Max Drawdown 3Y
FCF Payout Ratio10%65%

TMO Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

TMO found in:

IYH3.32%
XLV3.15%
VHT2.91%
MOAT1.44%
MGV0.88%
SCHG0.74%
VTV0.69%
IWD0.61%
SPYV0.59%
VONV0.55%
IVV0.37%
ESGV0.37%
SPLG0.36%
ITOT0.33%
SCHX0.31%
SCHB0.29%
VOO0.29%
VONE0.28%
SPY0.26%
VTI0.26%
SPTM0.24%
URTH0.23%
ACWI0.23%
RSP0.20%
VT0.16%
QUS0.09%
ONEO0.03%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

TMO vs ABBV: Head-to-Head Analysis

Thermo Fisher Scientific Inc. (TMO) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABBV leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, TMO generates a return on invested capital (ROIC) of 7.2% compared to ABBV's 8.3%. This suggests ABBV is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between TMO and ABBV is 0.397, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

TMO appears in 27 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, TMO or ABBV?

Our quantitative analysis compares TMO and ABBV across nine fundamental dimensions. ABBV wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are TMO and ABBV correlated?

The 252-day correlation between TMO and ABBV is 0.397. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.